How Trump helped Harvard: 5 ‘Crimson’ leadership lessons on standing up to bullies

Harvard has staged a notable institutional rebound after governance and reputational crises, reporting a record $629 million in FY25 current-use gifts (a 19% increase year-over-year), with over 22,000 gifts collected in a six-week period and total FY25 donations exceeding $600 million. The turnaround is attributed to a unified board, new leadership, sector-wide collective defense against Trump administration actions (including litigation), renewed alumni/donor engagement and a Morning Consult survey showing restored trust and rising international enrollments; the development signals improved financial resilience for the university but is unlikely to move broader financial markets.

Analysis

Market structure: The episode reinforces a governance premium — firms with unified, experienced boards and visible governance (example proxy: large-cap healthcare and industrials) will see relative P/E re-rating versus fractured peers. Direct beneficiaries: large defensives and reputationally inert businesses (MDT, MMM, TGT) and financials capturing wealthy donor flows (AXP). Losers: smaller education-adjacent services, partisan media exposed to reputational swings (FOXA) and any firm heavily reliant on federal favor.

Risk assessment: Tail risk includes an escalatory policy move (federal endowment tax or punitive sanctions) that could crystallize within 6–18 months and compress nonprofit asset allocations, reducing asset-manager fees and corporate donation-linked spend; probability moderate (20–30%) given political headlines. Immediate (days) volatility is headline-driven; short-term (weeks–months) depends on FY26 donation cycles and litigation outcomes; long-term (quarters) on legislation. Hidden dependency: philanthropic flows materially affect premium card spend and private wealth management revenues (AXP exposure).

Trade implications: Favor small, tactical longs in governance-strong large caps: establish 1–2% positions in MDT and MMM with 6–12 month targets of +10–15% and hard stops at -8%. Add 0.5–1% in TGT for consumer resilience (target +8% in 6–12 months). Use pair trade long MDT / short SYK (0.8x notional) to express relative med-tech durability. Employ defined-risk options: buy 6-month MDT 10–15% OTM call spreads and buy 1–2% notional VIX 3–6 month call exposure as tail hedge.

Contrarian angles: Consensus underestimates persistent philanthropic/wealth flows to financials; a continued rebound in gifts (FY25 precedent) benefits AXP merchant volumes — consider a tactical 0.5–1% long AXP if two consecutive quarters show donation-linked spend growth >3%. Reaction may be overdone toward FOXA and other politicized names; policy reversals are historically common (manufacturers vs tariffs), limiting long-term downside. Prepare for unintended consequences: a hard policy shock would favor hotel/flight insurers and volatility products — keep liquidity to add protection within 48–72 hours of legislative moves.

Key Decisions for Investors

• Establish a 1.5% long position in MDT (Medtronic) within 2–4 weeks, target +12% in 6–12 months, stop-loss -8%; hedge tail risk with a 6-month 10–15% OTM call spread (defined-cost upside).
• Add a 1% long in MMM (3M) for 6–12 month resilience, target +10%, stop-loss -8%; pair with 0.5% VIX call options (3–6 month) as political/regulatory tail protection.
• Initiate a 0.8x pair trade: long MDT vs short SYK (Stryker) sized to be revenue-neutral, to capture governance/brand premium in med-tech over the next 6–12 months.
• Tactically add 0.5–1% long in AXP if donation-linked consumer spend data (card volumes to universities/charities) shows sequential growth >3% over two quarters; exit if trend reverses or growth <1%.
• Avoid new longs in FOXA and other highly politicized media names for 30–60 days; consider a 1–2% short or put position only if litigation/regulatory headlines escalate (legislative action probability >30%).